T. Weiss

发表

Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia

S. Ogawa, T. Haferlach, Motohiro Kato, 2010, Haematologica.

IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients

T. Haferlach, S. Schnittger, W. Kern, 2009 .

AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

A. Kohlmann, T. Haferlach, S. Schnittger, 2010, Leukemia.

Histone epiproteomic profiling distinguishes oligodendroglioma, IDH-mutant and 1p/19q co-deleted from IDH-mutant astrocytoma and reveals less tri-methylation of H3K27 in oligodendrogliomas

A. Deimling, R. Aebersold, T. Weiss, 2019, Acta Neuropathologica.

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

S. Ogawa, A. Kohlmann, T. Haferlach, 2010, Blood.

Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T).

A. Kohlmann, T. Haferlach, S. Schnittger, 2009 .

RQ‐PCR based WT1 expression in comparison to BCR‐ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib‐treated chronic myeloid leukaemia

T. Haferlach, S. Schnittger, W. Kern, 2009, British journal of haematology.

leukemia identifies heterogeneous secondary genomic alterations SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid

S. Ogawa, A. Kohlmann, T. Haferlach, 2011 .

Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters

T. Haferlach, S. Schnittger, W. Kern, 2010, Genes, chromosomes & cancer.

Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy

T. Haferlach, S. Schnittger, W. Kern, 2008 .

Utility of immunohistochemistry markers in the interpretation of post-high-intensive focussed ultrasound prostate biopsy cores

S. Wach, A. Gaumann, T. Weiss, 2013, World Journal of Urology.

Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2010, Cancer genetics and cytogenetics.

Short communication Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2010 .

RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired

T. Haferlach, S. Schnittger, W. Kern, 2008 .

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

V. V. D. van der Velden, R. Hills, S. Schnittger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multifocal static creamy choroidal infiltrates. An early sign of lymphoid neoplasia.

T. Weiss, F. Jakobiec, T. Weiss, 1987, Ophthalmology.

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

T. Haferlach, B. Falini, S. Schnittger, 2009, Blood.

myeloproliferative neoplasms negative - leukemic transformation of Philadelphia chromosome Prevalence and prognostic impact of allelic imbalances associated with

S. Ogawa, L. Shih, A. Nagler, 2011 .

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.

D. Gilliland, S. Ogawa, T. Haferlach, 2009, Blood.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Paola Fazi, Marco Vignetti, Hans-Ulrich Klein, 2010, Blood.

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

T. Haferlach, J. Sundermann, S. Schnittger, 2010, Leukemia.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category

T. Haferlach, S. Schnittger, W. Kern, 2009, Annals of Hematology.

The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes

T. Haferlach, S. Schnittger, W. Kern, 2009, Cancer.

Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment

T. Haferlach, S. Schnittger, W. Kern, 2010, Leukemia.

[Basic principles of diagnosis and treatment of gliomas].

M. Weller, T. Weiss, P. Roth, 2018, Der Nervenarzt.

Multicentric non-enhancing lesions in glioblastoma: A retrospective study

A. Kanner, T. Weiss, T. Siegal, 2021, Journal of Clinical Neuroscience.

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

S. Ogawa, A. Kohlmann, T. Haferlach, 2010, Blood.